➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Express Scripts
Dow
Baxter
Johnson and Johnson

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESCITALOPRAM OXALATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Escitalopram Oxalate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00149825 Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome Completed National Institute of Mental Health (NIMH) Phase 2 2004-06-01 This study will examine the effectiveness of a combination of antidepressant medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression.
NCT00149825 Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome Completed Stanford University Phase 2 2004-06-01 This study will examine the effectiveness of a combination of antidepressant medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression.
NCT00222820 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed Mental Health Intervention Research Center (MHIRC) Phase 4 2002-04-01 We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person’s mood and anxiety and how these features affect a person’s capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person’s personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00222820 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed University of Pittsburgh Phase 4 2002-04-01 We are doing this pilot study to learn more about four aspects of treating depression: 1. The features of a depressed person’s mood and anxiety and how these features affect a person’s capacity to get better and stay better. 2. If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication. 3. Whether or not a person’s personality traits affect how they respond to treatment. 4. The gene involved in processing antidepressant medication
NCT00235508 Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed Sunovion Phase 4 2005-06-01 To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
NCT00387348 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated National Cancer Institute (NCI) Phase 3 2006-03-01 RATIONALE: Escitalopram may help improve depression and quality of life in patients with advanced lung or gastrointestinal cancer. It is not yet known whether escitalopram is more effective than a placebo in treating depression in patients with advanced lung or gastrointestinal cancer. PURPOSE: This randomized clinical trial is studying the side effects of escitalopram and to see how well it works compared to a placebo in treating depression in patients with advanced lung or gastrointestinal cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Escitalopram Oxalate

Condition Name

Condition Name for Escitalopram Oxalate
Intervention Trials
Depression 6
Healthy 4
Insomnia 2
Major Depressive Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Escitalopram Oxalate
Intervention Trials
Depression 10
Depressive Disorder 7
Depressive Disorder, Major 4
Fatigue 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Escitalopram Oxalate

Trials by Country

Trials by Country for Escitalopram Oxalate
Location Trials
United States 38
China 20
India 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Escitalopram Oxalate
Location Trials
Illinois 3
California 3
Massachusetts 2
Maryland 2
Indiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Escitalopram Oxalate

Clinical Trial Phase

Clinical Trial Phase for Escitalopram Oxalate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Escitalopram Oxalate
Clinical Trial Phase Trials
Completed 10
Recruiting 3
Terminated 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Escitalopram Oxalate

Sponsor Name

Sponsor Name for Escitalopram Oxalate
Sponsor Trials
Mylan Pharmaceuticals 2
Rehabilitation Institute of Chicago 2
National Cancer Institute (NCI) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Escitalopram Oxalate
Sponsor Trials
Other 14
Industry 8
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Baxter
Medtronic
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.